MEK inhibitors increase the mortality rate in mice with LPS-induced inflammation through IL-12-NO signaling
Open Access
- 13 October 2023
- journal article
- research article
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-13
Abstract
Lipopolysaccharide (LPS) is an endotoxin that can cause an acute inflammatory response. Nitric oxide (NO) is one of the most important innate immune system components and is synthesized by inducible NOS (iNOS) in macrophages in response to stimulation with LPS. LPS activates the RAS-RAF-mitogen-activated protein kinase/ERK kinase (MEK)-extracellular-signal-regulated kinase (ERK) signaling cascade in macrophages. The purpose of this study was to examine how the combination of LPS and MEK inhibitors, which have been used as anticancer agents in recent years, affects inflammation. We showed that MEK inhibitors enhanced iNOS expression and NO production in LPS-stimulated mouse bone marrow-derived macrophages. A MEK inhibitor increased the mortality rate in mice with LPS-induced inflammation. The expression of the cytokine interleukin-12 (IL-12) in macrophages was enhanced by the MEK inhibitor, as shown by a cytokine array and ELISA. IL-12 enhanced iNOS expression and NO production in response to LPS. We also showed that tumor necrosis factor (TNF-α) was secreted by macrophage after stimulation with LPS and that TNF-α and IL-12 synergistically induced iNOS expression and NO production. An anti-IL-12 neutralizing antibody prevented NO production and mortality in an LPS-induced inflammation mouse model in the presence of a MEK inhibitor. These results suggest that the MEK inhibitor increases the mortality rate in mice with LPS-induced inflammation through IL-12-NO signaling.Keywords
Funding Information
- MEXT | Japan Society for the Promotion of Science (JP20K19648, JP22K11711)
This publication has 57 references indexed in Scilit:
- Higher Activity of the Inducible Nitric Oxide Synthase Contributes to Very Early Onset Inflammatory Bowel DiseaseClinical and Translational Gastroenterology, 2014
- IL-27 promotes nitric oxide production induced by LPS through STAT1, NF-κB and MAPKsImmunobiology, 2013
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studiesBritish Journal of Dermatology, 2011
- IL-23 modulates CD56+/CD3- NK Cell and CD56+/CD3+ NK-like T Cell function differentially from IL-12International Immunology, 2008
- Interleukin-12, interleukin-23, and psoriasis: Current prospectsJournal of the American Academy of Dermatology, 2007
- A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease GeneScience, 2006
- Differential expression of inducible nitric oxide synthase and IL-12 between peritoneal and splenic macrophages stimulated with LPS plus IFN-γ is associated with the activation of extracellular signal-related kinaseInternational Immunology, 2006
- Differential regulation of interleukin‐12 p40 and p35 induction via Erk mitogen‐activated protein kinase‐dependent and ‐independent mechanisms and the implications for bioactive IL‐12 and IL‐23 responsesImmunology, 2003
- TNF-α Induction by LPS Is Regulated Posttranscriptionally via a Tpl2/ERK-Dependent PathwayCell, 2000
- Occlusive Vascular Disease in Psoriatic PatientsNew England Journal of Medicine, 1973